Drug-Eluting Bead Transarterial Chemoembolisation (DEB-TACE)

What is drug-eluting bead transarterial chemoembolisation (DEB-TACE)?

Drug-eluting bead transarterial chemoembolisation (DEB-TACE) is a minimally invasive treatment for liver cancer that uses tiny beads loaded with anti-cancer drugs to block the blood supply to a tumour and deliver chemotherapy directly to it. This targeted approach allows for a high concentration of drug at the tumour site, while minimising exposure to the rest of the body.

DEB-TACE is most commonly used in patients with:

• Unresectable hepatocellular carcinoma (HCC) – a type of primary liver cancer
• Liver metastases from cancers such as colorectal or neuroendocrine tumours

It is considered a palliative treatment – not intended to cure cancer, but to control tumour growth, relieve symptoms, and potentially extend life. DEB-TACE is typically offered when surgery, ablation or systemic therapy alone is not effective or suitable.

How it works

During DEB-TACE, a small catheter is inserted into the artery in the groin and guided into the hepatic artery using real-time X-ray imaging. Drug-eluting beads – microspheres loaded with chemotherapy (commonly doxorubicin) – are injected into the blood vessel feeding the tumour. These beads both block the tumour’s blood supply and slowly release chemotherapy over time, helping to maximise the cancer-fighting effect while reducing exposure to the rest of the body.

In some cases, the interventional radiologist may block off non-target arteries leading to other organs (such as the stomach or duodenum) using tiny coils to prevent unintended damage.

Conventional TACE vs DEB-TACE

DEB-TACE is a more refined version of conventional TACE and offers several clinical advantages:

• Better tumour response and more effective disease control
• Longer time to disease progression
• Lower risk of serious side effects such as liver toxicity
• More controlled drug release, resulting in fewer systemic side effects
• Improved tolerability, especially in patients with poor liver function or extensive disease
• Suitable for recurrent disease, bilobar liver involvement, and poorer performance status

For these reasons, DEB-TACE is increasingly preferred in patients who may not tolerate conventional chemoembolisation.

Why do you need DEB-TACE?

You may be offered DEB-TACE if:

• You have liver tumours that cannot be removed by surgery
• Your cancer has not responded well to systemic chemotherapy alone
• You have unresectable or recurrent hepatocellular carcinoma
• You have colorectal or neuroendocrine tumours with liver-dominant metastases
• Your doctor believes this treatment may extend survival or alleviate cancer-related symptoms

With continued treatment, DEB-TACE has been shown to delay cancer progression and may help extend life expectancy by 1–2 years in patients with unresectable liver cancer.

Who should not undergo DEB-TACE?

DEB-TACE is not suitable for all patients. It may not be recommended if you have:

• More than 75% of liver involvement
• Liver failure or severe liver cirrhosis
• Extensive disease outside the liver
• Severe heart, lung, or kidney disease
• Bone marrow suppression

Your doctor will assess your condition, liver function, and overall health before deciding if DEB-TACE is appropriate for you.

What are the risks and complications of DEB-TACE?

While DEB-TACE is generally safe and well tolerated, some side effects and complications can occur.

Common side effects

• Post-embolisation syndrome: abdominal pain, low-grade fever, nausea, and vomiting (worst in the first 24–48 hours; usually subsides within a week)
• Fatigue and appetite loss in the first few days after the procedure

Rare but possible complications

• Liver abscess
• Injury to the bile ducts
• Cholecystitis (inflammation of the gallbladder)
• Pancreatitis
• Non-target embolisation, causing injury to nearby organs
• Bleeding from the puncture site

Your medical team will monitor you closely during and after the procedure to manage any issues that arise.

How do you prepare for DEB-TACE?

You will receive specific instructions from your care team to prepare for the procedure.

Before your procedure

• Blood tests will be done to check liver and kidney function, and to ensure normal blood clotting
• Inform your doctor about all medications, including herbal supplements
• Let your care team know if you have any allergies to contrast dye, anaesthesia, or medications
• Stop blood thinners (e.g. aspirin, NSAIDs, warfarin) as advised by your doctor
• Women should inform their doctor if there is a possibility of pregnancy

If sedation is planned

• You will need to fast for 6 hours before the procedure
• You will likely need to stay overnight in hospital for monitoring

What can you expect during DEB-TACE?

Estimated duration

The procedure takes around 1.5 to 3 hours, followed by several hours of monitoring.

Before the procedure

• You’ll be admitted and an IV line will be placed
• The groin area will be cleaned and numbed with local anaesthetic
• Sedation may be given to help you relax

During the procedure

• A catheter is inserted into the groin artery and advanced into the hepatic artery
• Angiograms (X-ray roadmaps) are performed to locate the tumour’s blood supply
• Non-target arteries may be blocked with coils to prevent off-target effects
• Drug-eluting beads are injected to deliver chemotherapy and block blood flow to the tumour
• Once complete, the catheter is removed and firm pressure is applied to the puncture site
• You will be asked to lie flat for about 6 hours to reduce the risk of bleeding

After the procedure

• You may experience post-embolisation symptoms (pain, fever, nausea) which are managed with medications, including PCA (Patient Controlled Analgesia) if required
• Most patients are kept overnight for observation
• You will likely be discharged the next day if stable

Care and recovery after DEB-TACE

Expected recovery

• Most patients feel better within 7 days
• Side effects typically peak in the first 48 hours and gradually improve
• Many patients live normally between treatments

Recovery tips

• Rest for a few days after discharge
• Avoid heavy lifting or intense activity
• Keep the puncture site dry and clean
• Eat light, liver-friendly meals
• Take all prescribed medications
• Report any high fever, jaundice, or persistent abdominal pain to your doctor

Your recovery may depend on

• Liver function and overall health
• The extent and type of tumour
• Whether you experience post-procedure complications
• The need for repeat treatments

Follow-up and ongoing care

• Imaging tests (CT or MRI) to evaluate tumour response
• Blood tests to assess liver function and blood counts
• Follow-up consultations with your oncology or interventional radiology team

Repeat DEB-TACE may be required based on your clinical progress

DEB-TACE offers a more refined and tolerable approach to chemoembolisation, especially for patients with more advanced liver disease or those who may not respond well to traditional treatments. If you or a loved one are exploring treatment options for liver cancer, speak with your specialist team about whether DEB-TACE may be right for you.